Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)21.25
  • Today's Change1.20 / 5.99%
  • Shares traded1.53m
  • 1 Year change-11.83%
  • Beta0.5201
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4,1205,9477,783
Total Receivables, Net6991,106631
Total Inventory351678876
Prepaid expenses------
Other current assets, total11----
Total current assets5,1817,7309,290
Property, plant & equipment, net3,1343,1792,317
Goodwill, net------
Intangibles, net112163100
Long term investments4475045
Note receivable - long term238150122
Other long term assets------
Total assets9,31911,46911,874
LIABILITIES
Accounts payable104253843
Accrued expenses215206228
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,4591,6241,112
Other current liabilities, total813858692
Total current liabilities2,5922,9422,875
Total long term debt1,2411,076263
Total debt2,7002,7011,375
Deferred income tax--00.56
Minority interest13498553
Other liabilities, total199205188
Total liabilities4,0444,7213,879
SHAREHOLDERS EQUITY
Common stock247247247
Additional paid-in capital6,5956,5386,538
Retained earnings (accumulated deficit)(1461)1131,210
Treasury stock - common(106)(150)--
Unrealized gain (loss)------
Other equity, total(0.18)0.12--
Total equity5,2756,7487,995
Total liabilities & shareholders' equity9,31911,46911,874
Total common shares outstanding247247247
Treasury shares - common primary issue----0
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.